Skip to contentO
Ovid Therapeutics Inc.
O
OVIDOvid Therapeutics Inc. Released Aug 10, 2017, after the close
10-Q filed Aug 10, 2017, 41 days after period end · 0001564590-17-017251
Q2 2017 · 10-Q
Revenue—
Net Income-$10.25M-$10.25MN/M vs Q2 2016N/M vs Q1 2017 EPS Diluted-$0.57-$0.57
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ovid Therapeutics Inc. · CIK 1636651 · Engraved from SEC EDGAR
N/M vs Q1 2017
Operating Income-$10,288,100N/M Operating Cash Flowderived-$5,986,044N/M Free Cash Flowderived-$5,995,911N/M ended Jun 30, 2017 · filed Aug 10, 2017 · 41 d after period end
11.4% from the close of Aug 7, 2017 to the close of Aug 14, 2017, the first after the release.
after the close$7.53$6.67 May 31Aug 10Sep 13